NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Immunology


Return to Library

Free Immunology Articles


Studies conducted at Washington State University on genetics recently published



2009 AUG 4 - (NewsRx.com) -- Fresh data on genetics are presented in the report 'Generation of antigenic variants via gene conversion: Evidence for recombination fitness selection at the locus level in Anaplasma marginale.' "Multiple bacterial and protozoal pathogens utilize gene conversion to generate antigenically variant surface proteins to evade immune clearance and establish persistent infection. Both the donor alleles that encode the variants following recombination into an expression site and the donor loci themselves are under evolutionary selection: the alleles that encode variants that are sufficiently antigenically unique yet retain growth fitness and the loci that allow efficient recombination," researchers in the United States report.

"We examined allelic usage in generating Anaplasma marginale variants during in vivo infection in the mammalian reservoir host and identified preferential usage of specific alleles in the absence of immune selective pressure, consistent with certain individual alleles having a fitness advantage for in vivo growth. In contrast, the loci themselves appear to have been essentially equally selected for donor function in gene conversion with no significant effect of locus position relative to the expression site or origin of replication. This pattern of preferential allelic usage but lack of locus effect was observed independently for Msp2 and Msp3 variants, both generated by gene conversion. Furthermore, there was no locus effect observed when a single locus contained both msp2 and msp3 alleles in a tail-to-tail orientation flanked by a repeat. These experimental results support the hypothesis that predominance of specific variants reflects in vivo fitness as determined by the encoding allele, independent of locus structure and chromosomal position," wrote J.E. Futse and colleagues, Washington State University.

The researchers concluded: "Identification of highly fit variants provides targets for vaccines that will prevent the high-level bacteremia associated with acute disease."

Futse and colleagues published their study in Infection and Immunity (Generation of antigenic variants via gene conversion: Evidence for recombination fitness selection at the locus level in Anaplasma marginale. Infection and Immunity, 2009;77(8):3181-7).

For additional information, contact J.E. Futse, Washington State University, Dept. of Veterinary Microbiology and Pathology, Pullman, 99164 USA..

Publisher contact information for the journal Infection and Immunity is: Springer, 233 Spring Street, New York, NY 10013, USA.

Keywords: United States, Pullman, Genetics, Immunology.

This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2009, Life Science Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login